SNGX: Soligenix, Inc. Stock

by  •  • Comments Off on SNGX: Soligenix, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 4.39
Enterprise Value ($M) 1.31
Book Value ($M) 0.77
Book Value / Share 0.78
Price / Book 5.72
NCAV ($M) 0.53
NCAV / Share 0.54
Price / NCAV 8.32

Profitability (mra)
Return on Invested Capital (ROIC) -1.41
Return on Assets (ROA) -0.51
Return on Equity (ROE) -1.21

Liquidity (mrq)
Quick Ratio 1.08
Current Ratio 1.08

Balance Sheet (mrq) ($M)
Current Assets 7.82
Assets 8.06
Liabilities 7.29
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.84
Operating Income -7.70
Net Income -6.14
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -8.60
Cash from Investing 0.00
Cash from Financing 3.66

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐TRANSITION REPORT PURSUANT TO SE
2024-03-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2023 ☐TRANSITION REPORT PURSUAN
2023-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐TRANSITION REPORT PURSUANT T
2023-08-21 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐TRANSITION REPORT PURSUANT TO SEC

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 99,191 200,835 49.39
2024-07-25 43,635 265,848 16.41
2024-07-24 105,687 354,907 29.78
2024-07-23 56,063 222,854 25.16
2024-07-22 66,228 270,998 24.44

(click for more detail)

Similar Companies
SLS – SELLAS Life Sciences Group, Inc. SMFL – Smart for Life, Inc.
SNDL – SNDL Inc. SNOA – Sonoma Pharmaceuticals, Inc.
SNPX – Synaptogenix, Inc.


Financial data and stock pages provided by
Fintel.io